Traditional and Novel Dietary Interventions for Preventing Progression of Chronic Kidney Disease

Journal of Renal Nutrition

Volumn 23, Issue 3, 2013, Pages 241-245

  Kovesdy, Csaba P ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY FAILURE; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; DRUG EFFECT; HUMAN; INTESTINE; METABOLISM; POTASSIUM INTAKE; PROTEIN CALORIE MALNUTRITION; PROTEIN INTAKE; PROTEIN RESTRICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

DIET, PROTEIN-RESTRICTED; DIETARY PROTEINS; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; HUMANS; INTESTINES; POTASSIUM, DIETARY; PROTEIN-ENERGY MALNUTRITION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84876710988     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2013.02.001     Document Type: Review

References (37)

1. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
2. Levey A.S., Adler S., Caggiula A.W., et al. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis 1996, 27:652-663.
3. King A.J., Levey A.S. Dietary protein and renal function. J Am Soc Nephrol 1993, 3:1723-1737.
4. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994, 330:877-884.
5. Chauveau P., Combe C., Rigalleau V., et al. Restricted protein diet is associated with decrease in proteinuria: consequences on the progression of renal failure. J Ren Nutr 2007, 17:250-257.
6. Fouque D., Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2009, CD001892.
7. Menon V., Kopple J.D., Wang X., et al. Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 2009, 53:208-217.
8. Schwarz S., Trivedi B.K., Kalantar-Zadeh K., Kovesdy C.P. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006, 1:825-831.
9. Kovesdy C.P., Anderson J.E., Kalantar-Zadeh K. Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clin Nephrol 2010, 73:268-275.
10. Kovesdy C.P., Kuchmak O., Lu J.L., Kalantar-Zadeh K. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 2010, 56:842-851.
11. Barsotti G., Morelli E., Giannoni A., Guiducci A., Lupetti S., Giovannetti S. Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: a controlled trial. Kidney Int Suppl 1983, 16:S278-S284.
12. Motojima M., Nishijima F., Ikoma M., et al. Role for "uremic toxin" in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991, 40:461-469.
13. Niwa T., Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994, 124:96-104.
14. Schulman G., Agarwal R., Acharya M., Berl T., Blumenthal S., Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006, 47:565-577.
15. Koide K., Koshikawa S., Yamane K. Clinical evaluation of AST-120 on suppression of progression of chronic renal failure. Multi-center, double blind study in comparison with placebo. Clin Eval 1987, 15:527-564.
16. Konishi K., Nakano S., Tsuda S., Nakagawa A., Kigoshi T., Koya D. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Res Clin Pract 2008, 81:310-315.
17. Nakamura T., Kawagoe Y., Matsuda T., et al. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res 2004, 27:121-126.
18. Niwa T., Nomura T., Sugiyama S., Miyazaki T., Tsukushi S., Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 1997, 62:S23-S28.
19. Owada A., Shiigai T. Effects of oral adsorbent AST-120 concurrent with a low-protein diet on the progression of chronic renal failure. Am J Nephrol 1996, 16:124-127.
20. Shoji T., Wada A., Inoue K., et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract 2007, 105:c99-c107.
21. Yorioka N., Ito T., Masaki T., et al. Dose-dependent effect of an oral adsorbent, AST-120, in patients with early chronic renal failure. J Int Med Res 2002, 30:467-475.
22. Akizawa T., Asano Y., Morita S., et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009, 54:459-467.
23. Outcome of global phase III (EPPIC) studies. Available at: Accessed on March 8, 2013. http://www.mt-pharma.co.jp/e/release/nr/2012/pdf/eMTPC121010_K.pdf.
24. Kovesdy C.P., Regidor D.L., Mehrotra R., et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2007, 2:999-1007.
25. Hayes J., Kalantar-Zadeh K., Lu J.L., Turban S., Anderson J.E., Kovesdy C.P. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract 2012, 120:c8-c16.
26. Conn J.W., Johnson R.D. Kaliopenic nephropathy. Am J Clin Nutr 1956, 4:523-528.
27. Cremer W., Bock K.D. Symptoms and course of chronic hypokalemic nephropathy in man. Clin Nephrol 1977, 7:112-119.
28. Elger M., Bankir L., Kriz W. Morphometric analysis of kidney hypertrophy in rats after chronic potassium depletion. Am J Physiol 1992, 262:F656-F667.
29. Riemenschneider T., Bohle A. Morphologic aspects of low-potassium and low-sodium nephropathy. Clin Nephrol 1983, 19:271-279.
30. Torres V.E., Young W.F., Offord K.P., Hattery R.R. Association of hypokalemia, aldosteronism, and renal cysts. N Engl J Med 1990, 322:345-351.
31. Menahem S.A., Perry G.J., Dowling J., Thomson N.M. Hypokalaemia-induced acute renal failure. Nephrol Dial Transplant 1999, 14:2216-2218.
32. Epstein F.H. Signs and symptoms of electrolyte disorders. Clinical disorders of fluid and electrolyte metabolism 1980, 499. McGraw-Hill, New York, NY. 3rd ed. M.H. Maxwell, C.R. Kleeman (Eds.).
33. Fisch C. Electrolytes and the heart. The Heart 1982, 1599. McGraw-Hill, New York, NY. J.W. Hurst (Ed.).
34. Kleeman K., Singh B.N. Serum electrolytes and the heart. Clinical disorders of fluid and electrolyte metabolism 1980, 145. McGraw-Hill, New York, NY. 3rd ed. M.H. Maxwell, C.R. Kleeman (Eds.).
35. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
36. Zhang L., Wang F., Wang L., et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012, 379:815-822.
37. Kovesdy C.P., Kalantar-Zadeh K. Enter the dragon: a Chinese epidemic of chronic kidney disease?. Lancet 2012, 379:783-785.